Why Analysts Lost Confidence in the Arcturus COVID-19 Vaccine
Arcturus Therapeutics shares took a tumble on Tuesday after the company announced update on its COVID-19 vaccine candidate.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares tumbling on Tuesday. While the company did receive approval from the Singapore Health Sciences Authority to proceed with a Phase 2 clinical study of its vaccine candidate ARCT-021, the data seemed to be underwhelming.
Note that the approval is based on data from the Phase 1/2 trial that demonstrated the vaccine produced neutralizing antibodies after one dose. However, these neutralizing antibodies were at lower levels than rival vaccine candidates. Arcturus is hoping its vaccine will not require a booster shot, making it easier to administer than vaccines that require two doses.
Looking forward, Arcturus expects to be on its way with Phase 2 in early 2021 and will be looking for optimal dosing levels to start a global Phase 3 trial in the second quarter of 2021.
As a result, H.C. Wainwright downgraded the stock to Neutral with a $50 price target. Analyst Ed Arce noted in the call that the firm has lost confidence in the potential of ARCT-021 to provide meaningful protection from SARS-CoV-2 infection and COVID-19.
[nativounit]
Raymond James also downgraded Arcturus to Market Perform from Outperform, citing that the data was “underwhelming.” The firm went on to detail:
While this latest dataset does not completely impair single-shot ARCT-021, which may provide protection against COVID-19 infection in Phase 3, the lack of SARS-CoV-2 neutralizing antibody (NAb) titers at or above levels seen in convalescent sera reduces our confidence that ARCT-021 will be able to achieve competitive levels of vaccine efficacy with single-shot dosing. … At a minimum, the question will be asked by the market and unanswered until Phase 3, thereby limiting near-term upside and justifying a Market Perform rating.
Arcturus Therapeutics stock traded down 52% on Tuesday to $43.96, in a 52-week range of $8.51 to $129.71. The consensus price target is $106.15.
[recirclink id=826537][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
